Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
70
ALLO Quote, Financials, Valuation and Earnings
Last price:
$2.07
Seasonality move
:
-11.41%
Day range:
$2.06 - $2.30
52-week range:
$0.86 - $2.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,442.58x
P/B ratio:
1.52x
Volume:
5.9M
Avg. volume:
6.4M
1-year change:
-18.08%
Market cap:
$478.7M
Revenue:
$22K
EPS (TTM):
-$0.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALLO
Allogene Therapeutics, Inc.
|
$2K | -$0.22 | -92.41% | -23.1% | $7.38 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$39.00 | -- | -94.17% | $4.0000 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALLO
Allogene Therapeutics, Inc.
|
$2.13 | $7.38 | $478.7M | -- | $0.00 | 0% | 2,442.58x |
|
AGEN
Agenus, Inc.
|
$3.21 | $12.33 | $116M | -- | $0.00 | 0% | 0.81x |
|
CRIS
Curis, Inc.
|
$1.14 | $14.00 | $14.7M | -- | $0.00 | 0% | 1.09x |
|
LADX
LadRx Corp.
|
$0.10 | -- | $51.2K | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.29 | $5.50 | $40.2M | -- | $0.00 | 0% | 4.69x |
|
WINT
Windtree Therapeutics, Inc.
|
$0.0120 | $4.0000 | $404.5K | 0.00x | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALLO
Allogene Therapeutics, Inc.
|
21.26% | -0.209 | 30.77% | 7.92x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
WINT
Windtree Therapeutics, Inc.
|
974.23% | 2.926 | 568.87% | 0.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALLO
Allogene Therapeutics, Inc.
|
-$3.1M | -$44.9M | -44.62% | -54.89% | -315927.27% | -$29.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
WINT
Windtree Therapeutics, Inc.
|
-$360K | -$3.8M | -320.18% | -760.4% | -- | -$6.4M |
Allogene Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ALLO or AGEN?
Agenus, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of -116.82%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About ALLO or AGEN?
Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 246.64%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 284.22%. Given that Agenus, Inc. has higher upside potential than Allogene Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Allogene Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.10 1 0 AGENAgenus, Inc.2 1 0 -
Is ALLO or AGEN More Risky?
Allogene Therapeutics, Inc. has a beta of 0.603, which suggesting that the stock is 39.696% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock ALLO or AGEN?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALLO or AGEN?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 0.81x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M AGENAgenus, Inc.0.81x -- $30.2M $63.9M
-
Which has Higher Returns ALLO or CRIS?
Curis, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of -243.36%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About ALLO or CRIS?
Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 246.64%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1128.07%. Given that Curis, Inc. has higher upside potential than Allogene Therapeutics, Inc., analysts believe Curis, Inc. is more attractive than Allogene Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.10 1 0 CRISCuris, Inc.4 0 0 -
Is ALLO or CRIS More Risky?
Allogene Therapeutics, Inc. has a beta of 0.603, which suggesting that the stock is 39.696% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock ALLO or CRIS?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALLO or CRIS?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 1.09x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M CRISCuris, Inc.1.09x -- $3.2M -$7.7M
-
Which has Higher Returns ALLO or LADX?
LadRx Corp. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of --. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About ALLO or LADX?
Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 246.64%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Allogene Therapeutics, Inc., analysts believe LadRx Corp. is more attractive than Allogene Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.10 1 0 LADXLadRx Corp.0 0 0 -
Is ALLO or LADX More Risky?
Allogene Therapeutics, Inc. has a beta of 0.603, which suggesting that the stock is 39.696% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock ALLO or LADX?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALLO or LADX?
Allogene Therapeutics, Inc. quarterly revenues are --, which are larger than LadRx Corp. quarterly revenues of --. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns ALLO or PSTV?
Plus Therapeutics, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of -316.61%. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About ALLO or PSTV?
Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 246.64%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than Allogene Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Allogene Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.10 1 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is ALLO or PSTV More Risky?
Allogene Therapeutics, Inc. has a beta of 0.603, which suggesting that the stock is 39.696% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock ALLO or PSTV?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALLO or PSTV?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M PSTVPlus Therapeutics, Inc.4.69x -- $1.4M -$4.4M
-
Which has Higher Returns ALLO or WINT?
Windtree Therapeutics, Inc. has a net margin of -295454.55% compared to Allogene Therapeutics, Inc.'s net margin of --. Allogene Therapeutics, Inc.'s return on equity of -54.89% beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.
Company Gross Margin Earnings Per Share Invested Capital ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M -
What do Analysts Say About ALLO or WINT?
Allogene Therapeutics, Inc. has a consensus price target of $7.38, signalling upside risk potential of 246.64%. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 33233.33%. Given that Windtree Therapeutics, Inc. has higher upside potential than Allogene Therapeutics, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Allogene Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALLOAllogene Therapeutics, Inc.10 1 0 WINTWindtree Therapeutics, Inc.0 0 0 -
Is ALLO or WINT More Risky?
Allogene Therapeutics, Inc. has a beta of 0.603, which suggesting that the stock is 39.696% less volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.733%.
-
Which is a Better Dividend Stock ALLO or WINT?
Allogene Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics, Inc. pays -- of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALLO or WINT?
Allogene Therapeutics, Inc. quarterly revenues are --, which are smaller than Windtree Therapeutics, Inc. quarterly revenues of --. Allogene Therapeutics, Inc.'s net income of -$41.4M is lower than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Allogene Therapeutics, Inc.'s price-to-earnings ratio is -- while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics, Inc. is 2,442.58x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 1.44% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 0.45% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.32% over the past day.
